GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » ROC %

Zeo ScientifiX (Zeo ScientifiX) ROC % : -459.12% (As of Jan. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Zeo ScientifiX's annualized return on capital (ROC %) for the quarter that ended in Jan. 2024 was -459.12%.

As of today (2024-06-13), Zeo ScientifiX's WACC % is 19.21%. Zeo ScientifiX's ROC % is -287.13% (calculated using TTM income statement data). Zeo ScientifiX earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Zeo ScientifiX ROC % Historical Data

The historical data trend for Zeo ScientifiX's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX ROC % Chart

Zeo ScientifiX Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -239.51 -1,360.09 -913.22 -339.79 -267.68

Zeo ScientifiX Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -294,950.86 -326.24 -279.89 -259.23 -459.12

Zeo ScientifiX ROC % Calculation

Zeo ScientifiX's annualized Return on Capital (ROC %) for the fiscal year that ended in Oct. 2023 is calculated as:

ROC % (A: Oct. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Oct. 2022 ) + Invested Capital (A: Oct. 2023 ))/ count )
=-6.767 * ( 1 - 0% )/( (3.299 + 1.757)/ 2 )
=-6.767/2.528
=-267.68 %

where

Zeo ScientifiX's annualized Return on Capital (ROC %) for the quarter that ended in Jan. 2024 is calculated as:

ROC % (Q: Jan. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2023 ) + Invested Capital (Q: Jan. 2024 ))/ count )
=-4648 * ( 1 - 0% )/( (1.757 + 2023)/ 2 )
=-4648/1012.3785
=-459.12 %

where

Note: The Operating Income data used here is four times the quarterly (Jan. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zeo ScientifiX  (OTCPK:ZEOX) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Zeo ScientifiX's WACC % is 19.21%. Zeo ScientifiX's ROC % is -287.13% (calculated using TTM income statement data). Zeo ScientifiX earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Zeo ScientifiX ROC % Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zeo ScientifiX (Zeo ScientifiX) Business Description

Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Executives
Skycrest Holdings, Llc 10 percent owner 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider director, officer: CEO and Director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub officer: Executive Vice President & CSO 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich officer: COO and Acting CEO 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser director 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn director 2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz director 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi director 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh director E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste director
Ryan C Likes officer: Chief Operating Officer 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell 10 percent owner, officer: Chief Financial Officer 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani director, officer: Chief Executive Officer 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140